TY - JOUR
T1 - Circulating fatty acids and prostate cancer risk
T2 - Individual participant meta-analysis of prospective studies
AU - Crowe, Francesca L.
AU - Appleby, Paul N.
AU - Travis, Ruth C.
AU - Barnett, Matt
AU - Brasky, Theodore M.
AU - Bueno-De-mesquita, H. Bas
AU - Chajes, Veronique
AU - Chavarro, Jorge E.
AU - Chirlaque, Maria Dolores
AU - English, Dallas R.
AU - Gibson, Robert A.
AU - Giles, Graham G.
AU - Goodman, Gary E.
AU - Henning, Susanne M.
AU - Kaaks, Rudolf
AU - King, Irena B.
AU - Kolonel, Lawrence N.
AU - Kristal, Alan R.
AU - Neuhouser, Marian L.
AU - Park, Song Yi
AU - Severi, Gianluca
AU - Siddiq, Afshan
AU - Stampfer, Meir J.
AU - Stattin, Pär
AU - Tangen, Catherine M.
AU - Tjønneland, Anne
AU - Trichopoulos, Dimitrios
AU - Tumino, Rosario
AU - Wilkens, Lynne R.
AU - Key, Timothy J.
AU - Allen, Naomi E.
N1 - Funding Information:
Centralized pooling, checking, and analysis of data were supported by Cancer Research UK (grant number C570/A11691). We thank the men who participated in the collaborating studies, the research staff, the collaborating laboratories, and the funding agencies in each of the studies. The Carotene and Retinol Efficacy Trial was supported by the National Cancer Institute at the National Institutes of Health (grants R01CA96789, U01CA63673, and N01PC35142). The Physicians’ Health Study was supported by the US Department of Defence (grant W81XWH-11-1-0529) and the National Institutes of Health (grants CA42182, CA58684, CA90598, CA141298 CA97193, CA34944, CA40360, CA131945, P50CA90381, 1U54CA155626-01, P30DK046200, HL26490, and HL34595). SWOG’s contribution of data from the Prostate Cancer Prevention Trial and the Selenium and Vitamin E Cancer Prevention Trial was supported by a NCI/ DCP grant (CA37429).
Publisher Copyright:
© The Author 2014. Published by Oxford University Press. All rights reserved.
PY - 2014/9/1
Y1 - 2014/9/1
N2 - Background: Individual studies have suggested that some circulating fatty acids are associated with prostate cancer risk, but have not been large enough to provide precise estimates of associations, particularly by stage and grade of disease.Methods: Principal investigators of prospective studies on circulating fatty acids and prostate cancer were invited to collaborate. Investigators provided individual participant data on circulating fatty acids (weight percent) and other characteristics of prostate cancer cases and controls. Prostate cancer risk by study-specific fifths of 14 fatty acids was estimated using multivariable-adjusted conditional logistic regression. All statistical tests were two-sided.Conclusion: There was no strong evidence that circulating fatty acids are important predictors of prostate cancer risk. It is not clear whether the modest associations of stearic, eicosapentaenoic, and docosapentaenoic acid are causal.Results: Five thousand and ninety-eight case patients and 6649 control patients from seven studies with an average follow-up of 5.1 (SD = 3.3) years were included. Stearic acid (18:0) was inversely associated with total prostate cancer (odds ratio [OR] Q5 vs Q1 = 0.88, 95% confidence interval [CI] = 0.78 to 1.00, Ptrend =.043). Prostate cancer risk was, respectively, 14% and 16% greater in the highest fifth of eicosapentaenoic acid (20:5n-3) (OR = 1.14, 95% CI = 1.01 to 1.29, Ptrend =.001) and docosapentaenoic acid (22:5n-3) (OR = 1.16, 95% CI = 1.02 to 1.33, Ptrend =.003), but in each case there was heterogeneity between studies (P =.022 and P <.001, respectively). There was heterogeneity in the association between docosapentaenoic acid and prostate cancer by grade of disease (P =.006); the association was statistically significant for low-grade disease but not high-grade disease. The remaining 11 fatty acids were not statistically associated with total prostate cancer risk.
AB - Background: Individual studies have suggested that some circulating fatty acids are associated with prostate cancer risk, but have not been large enough to provide precise estimates of associations, particularly by stage and grade of disease.Methods: Principal investigators of prospective studies on circulating fatty acids and prostate cancer were invited to collaborate. Investigators provided individual participant data on circulating fatty acids (weight percent) and other characteristics of prostate cancer cases and controls. Prostate cancer risk by study-specific fifths of 14 fatty acids was estimated using multivariable-adjusted conditional logistic regression. All statistical tests were two-sided.Conclusion: There was no strong evidence that circulating fatty acids are important predictors of prostate cancer risk. It is not clear whether the modest associations of stearic, eicosapentaenoic, and docosapentaenoic acid are causal.Results: Five thousand and ninety-eight case patients and 6649 control patients from seven studies with an average follow-up of 5.1 (SD = 3.3) years were included. Stearic acid (18:0) was inversely associated with total prostate cancer (odds ratio [OR] Q5 vs Q1 = 0.88, 95% confidence interval [CI] = 0.78 to 1.00, Ptrend =.043). Prostate cancer risk was, respectively, 14% and 16% greater in the highest fifth of eicosapentaenoic acid (20:5n-3) (OR = 1.14, 95% CI = 1.01 to 1.29, Ptrend =.001) and docosapentaenoic acid (22:5n-3) (OR = 1.16, 95% CI = 1.02 to 1.33, Ptrend =.003), but in each case there was heterogeneity between studies (P =.022 and P <.001, respectively). There was heterogeneity in the association between docosapentaenoic acid and prostate cancer by grade of disease (P =.006); the association was statistically significant for low-grade disease but not high-grade disease. The remaining 11 fatty acids were not statistically associated with total prostate cancer risk.
UR - http://www.scopus.com/inward/record.url?scp=84928590183&partnerID=8YFLogxK
U2 - 10.1093/jnci/dju240
DO - 10.1093/jnci/dju240
M3 - Review article
C2 - 25210201
AN - SCOPUS:84928590183
VL - 106
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
SN - 0027-8874
IS - 9
ER -